The Boston Globe profiles the drug development work of Acceleron, which hopes to develop a therapy that regulates body tissues and systems. To help illustrate its efforts, researchers point to a picture of the Belgian blue, a white bull with enormous muscles. The company believes the same kind of genetics at work in the Belgian blue would help repair the harsh physical damage of such diseases as ALS, muscular dystrophy, and cancer. The company has raised $56 million from top-tier venture capital groups.
- read the Boston Globe article